Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.

Author: AugustineCarole, BrewerClaudette, HeftingNanco, HobartMary, JosiassenMette Krog, McQuadeRobert D, SanchezRaymond, SkubanAleksandar, ZhangPeter

Paper Details 
Original Abstract of the Article :
OBJECTIVE: To assess the efficacy, safety, and tolerability of brexpiprazole as adjunctive treatment in adults with major depressive disorder (MDD) and an inadequate response to prior antidepressant treatment (ADT). METHODS: Patients with a current major depressive episode after prior treatment wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1080/03007995.2018.1430220

データ提供:米国国立医学図書館(NLM)

Brexpiprazole: An Adjunctive Treatment for Major Depressive Disorder

Major depressive disorder (MDD) is a challenging mental health condition, like a thick fog obscuring the path to happiness. This study, like a beacon of hope in the fog, investigates the efficacy and safety of brexpiprazole as an adjunctive treatment for MDD. The researchers, like skilled navigators charting a course through the fog, conducted a randomized, controlled trial, comparing brexpiprazole to placebo and quetiapine extended-release. Their findings, like a clearing in the fog, show that brexpiprazole significantly improved symptoms of depression compared to placebo, suggesting its potential as a valuable tool for treating MDD.

Hope for MDD Treatment

This study offers promising results for patients struggling with MDD. Brexpiprazole, like a guiding star in the night sky, appears to be a safe and effective adjunctive treatment for those who haven't found relief from traditional antidepressants. These findings provide hope for improved treatment options and better management of MDD.

Managing Mental Health

Mental health is an integral part of overall well-being. This study highlights the importance of research and innovation in developing new and effective treatments for mental health conditions. By exploring different medications and treatment approaches, we can better navigate the complexities of mental health and provide support to those in need.

Dr.Camel's Conclusion

This study shines a light on the potential of brexpiprazole as an adjunctive treatment for MDD, offering hope for those who haven't found relief from traditional therapies. The researchers, like explorers venturing into new territory, have provided valuable insights into the efficacy and safety of brexpiprazole, paving the way for improved treatment options and a brighter future for those battling depression.

Date :
  1. Date Completed 2019-07-01
  2. Date Revised 2019-07-01
Further Info :

Pubmed ID

29343128

DOI: Digital Object Identifier

10.1080/03007995.2018.1430220

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.